ImmunityBio (IBRX) Securities Lawsuit 2026 Are You Part of the Class?
Investors filed a federal securities class action lawsuit against ImmunityBio, Inc. (NASDAQ: IBRX) and certain of its executives after the FDA publicly released a warning letter accusing the company of making false and misleading claims about its cancer drug Anktiva. The lawsuit was filed in the United States District Court for the Central District of…
